Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).


Open article in different language:  DE  |  FR  |  IT
Art. 9 Consequences of revocation of consent

1 If con­sent is re­voked, the bio­lo­gic­al ma­ter­i­al and health‑re­lated per­son­al data of the per­son con­cerned must be an­onymised after data eval­u­ation has been com­pleted.

2 An­onymisa­tion of the bio­lo­gic­al ma­ter­i­al and per­son­al data may be dis­pensed with if:

a.
the per­son con­cerned ex­pressly re­nounces this right when re­vok­ing con­sent; or
b.
it is es­tab­lished at the be­gin­ning of the clin­ic­al tri­al that an­onymisa­tion is not pos­sible and the per­son con­cerned, hav­ing been ad­equately in­formed of this fact, con­sen­ted to par­ti­cip­ate.

3 Per­sons re­vok­ing con­sent must be offered any fol­low-up care re­quired to pro­tect their health.

Diese Seite ist durch reCAPTCHA geschützt und die Google Datenschutzrichtlinie und Nutzungsbedingungen gelten.

Feedback
Laden